Education
About Us
Working with TipRanks
Follow Us
Chordate Medical Holding AB (SE:CMH)
:CMH
Top Page
Chordate Medical Holding AB
(CMH)
Select Model
Select Model
Rating:42Neutral
Price Target:
kr0.94
▲(53.28% Upside)
The score is held down primarily by weak financial performance (persistent losses and cash burn with unstable revenue). Technical indicators also point to a sustained downtrend. Valuation provides limited offset given negative earnings and no dividend support, while earnings-call and corporate-event inputs were not available.
Chordate Medical Holding AB (CMH) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr2.06M
Dividend YieldN/A
Average Volume (3M)5.37K
Price to Earnings (P/E)―
Beta (1Y)1.03
Revenue GrowthN/A
EPS GrowthN/A
CountrySE
Employees3
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,699,620
10 Day Avg. Volume6,244
30 Day Avg. Volume5,373
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.00
Price to Sales (P/S)13.84
P/FCF Ratio-0.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Chordate Medical Holding AB Business Overview & Revenue Model
Company DescriptionChordate Medical Holding AB (publ), a medical technology company, develops products and solutions for the treatment of chronic migraine and rhinitis in Sweden. It focuses on the ear-nose and throat area. The company was founded in 2005 and is based in Kista, Sweden.
How the Company Makes Money
Chordate Medical Holding AB Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.04M | 664.69K | 976.28K | 108.52K | 882.05K | 618.01K |
| Gross Profit | 847.34K | 1.99M | 1.31M | 34.06K | 1.93M | 2.51M |
| EBITDA | -23.43M | -25.23M | -27.94M | -26.79M | -20.50M | -18.05M |
| Net Income | -25.16M | -27.25M | -29.19M | -27.94M | -21.77M | -19.76M |
Balance Sheet | ||||||
| Total Assets | 18.04M | 17.53M | 21.96M | 18.64M | 44.06M | 31.22M |
| Cash, Cash Equivalents and Short-Term Investments | 4.24M | 2.53M | 8.46M | 3.68M | 28.98M | 15.54M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 4.14M | 8.34M | 6.87M | 7.57M | 5.11M | 5.58M |
| Stockholders Equity | 13.90M | 9.20M | 15.09M | 11.07M | 38.95M | 25.64M |
Cash Flow | ||||||
| Free Cash Flow | -25.13M | -27.29M | -28.41M | -25.37M | -21.64M | -20.55M |
| Operating Cash Flow | -24.69M | -24.41M | -27.26M | -24.98M | -20.34M | -17.43M |
| Investing Cash Flow | -991.62K | -2.88M | -1.16M | -389.49K | -1.30M | -3.12M |
| Financing Cash Flow | 18.41M | 21.36M | 33.20M | 65.21K | 35.08M | 32.54M |
Chordate Medical Holding AB Peers Comparison
UnderperformOutperform
Sector (51)
SE:CMH
Chordate Medical Holding AB
0.76
-10.50
-93.23%
DE:4HG0
Qlife Holding AB
0.18
0.03
21.05%
DE:2OK
SpectraCure AB
0.01
-0.09
-90.00%
DE:LUR
Luxbright AB
0.04
-0.02
-38.10%
DE:7820
Scandinavian Real Heart AB
1.25
0.40
46.99%
SE:SDOS
ScandiDos AB
1.19
-0.40
-25.16%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.